TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03493386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 2 mg tablet
Description: Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 2 mg tablet
Description: Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablet
Description: Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablet
Description: Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablet
Description: Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg tablet
Description: Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
Study: NCT04671186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle (Lactobacillus rhamnosus strain GG)
Description: Culturelle probiotics are typically sold over the counter as dietary supplements Probiotics group will take 1 capsule of probiotics orally once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will take 1 capsule of placebo orally once daily
Study: NCT01020955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NutropinAq (GH) and Increlex (IGF-I)
Description: NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NutropinAq and placebo
Description: NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
Study: NCT00655876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m\^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m\^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m\^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m\^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
Study: NCT03082287

Intervention type: DEVICE
Intervention: Fecal Calprotectin Level
Description: Measurement of calprotectin in feces

Intervention type: DEVICE
Intervention: Fecal Calprotectin Level
Description: Measurement of calprotectin in feces

Intervention type: DEVICE
Intervention: Fecal Calprotectin Level
Description: Measurement of calprotectin in feces

Intervention type: DEVICE
Intervention: Fecal Calprotectin Level
Description: Measurement of calprotectin in feces
Study: NCT04269538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06480605
Description: PF-06480605 150 mg and 450 mg SC dosing
Study: NCT03307278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: House dust mite
Description: As a stimulant to induce inflammasome activation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: House dust mite
Description: As a stimulant to induce inflammasome activation
Study: NCT03858413

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT03323216

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the intervention and 6 months after the intervention.
Study: NCT02332577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRISTINAMYCIN XRP7263
Description: Pharmaceutical form:tablet 500 mg Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Pharmaceutical form:capsule 500 mg Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Placebo
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRISTINAMYCIN Placebo
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT02409667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
Study: NCT01784575

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator Intervention
Description: The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
Study: NCT04269538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC dosing
Study: NCT02731326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor
Description: The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud.
Study: NCT02708992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Study: NCT01784575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigator Intervention
Description: The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
Study: NCT00081328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: capsule, 1000 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: capsule, 1000 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: capsule, 1000 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: capsule, 4 mg bid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Program
Description: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
Study: NCT00044525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY59-8862 (Cytotoxic Taxane)
Description: 1 h intravenous infusion every 3 weeks
Study: NCT03111342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia
Description: A 2% lidocaine without vasoconstrictor injection into the cervix

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry-needling
Description: A placement of thin needle into the cervix without substance injection
Study: NCT01727557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: Regional anesthesia will be compared to local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: Regional anesthesia will be compared to local anesthesia
Study: NCT03912831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).
Study: NCT02731326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Altering Messaging
Description: Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
Study: NCT00003224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: vaccine adjuvant
Study: NCT03912831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-439
Description: A single infusion of E7 TCR T cells (KITE-439).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.
Study: NCT00003224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Description: vaccine adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA (incomplete Freund's adjuvant)
Description: Peptides emulsified in IFA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA (incomplete Freund's adjuvant)
Description: Peptides emulsified in IFA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFA (incomplete Freund's adjuvant)
Description: Peptides emulsified in IFA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946
Description: This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946
Description: This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946
Description: This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946
Description: This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
Study: NCT03912831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Administered subcutaneously.
Study: NCT00003224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946/tet-p
Description: This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p946/tet-p
Description: This peptide is a longer version of p946 (gp100 \[280-288\]) sythesized colinearly with the tetanus helper peptide (Tet-p)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tet-p
Description: modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tet-p
Description: modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
Study: NCT02928367

Intervention type: OTHER
Intervention: rectal swab
Description: rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)

Intervention type: OTHER
Intervention: rectal swab
Description: rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)

Intervention type: OTHER
Intervention: blood draw
Description: blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)

Intervention type: OTHER
Intervention: blood draw
Description: blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
Study: NCT00373698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Component Model of Collaborative Care
Description: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
Study: NCT01788618

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive exams
Description: Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive exams
Description: Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)

Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive exams
Description: Psychopathological assessment (T0 and T3):~* Scale of Spielberger~* The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)

Intervention type: OTHER
Group type: OTHER
Intervention: standardized cognitive rehabilitation
Description: Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized home exercise
Description: These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog

Intervention type: OTHER
Group type: OTHER
Intervention: Follow up by phone
Description: These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
Study: NCT00995280

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single lumen needle oocyte retrieval
Description: single lumen needle use during oocyte retrieval

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double lumen needle oocyte retrieval
Description: double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
Study: NCT04013321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepScore Max coaching feature
Description: The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBTi
Description: Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
Study: NCT02854592

Intervention type: DRUG
Intervention: rtPA
Description: intravenous thrombolysis with rtPa

Intervention type: DRUG
Intervention: urokinase
Description: intravenous thrombolysis with urokinase
Study: NCT00593047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KB2115
Description: tablet formulation given once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB2115
Description: tablet formulation given once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB2115
Description: tablet formulation given once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB2115
Description: tablet formulation given once daily for 12 weeks
Study: NCT01267994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
Study: NCT00097903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin (BNP1350)
Description: Phase 1 study,dose-escalation design
Study: NCT02538848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD4010
Description: injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD4010
Description: injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD4010
Description: injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTD4010
Description: injectable solution
Study: NCT02878122

Intervention type: PROCEDURE
Intervention: Cancer treatment
Description: Chemotherapy and laparoscopic surgery